Development code · Small Molecule
AGN-241751
AGN-241751 is a development code for Zelquistinel (GATE-251), developed by Syndeio Biosciences, Inc..
- Status
- Phase 2 for Major depressive disorder
- Mechanism
- GluN2B PAM
- Developer
- Syndeio Biosciences, Inc.
Programs
- Zelquistinel (GATE-251) for Major depressive disorderPhase 2Recruiting
Also known as
- GATE-251
- Zelquistinel